Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license ...

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...

Zag Bio announced the company’s launch with a $80 million financing round, which includes a recently closed Series A ...

PE: What impact will DTC programs have on generic drug prices? O’Dell: Not much today, but generics are not completely immune ...

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to ...

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...

Organon announced that CEO Kevin Ali intends to resign from his position following results from an internal investigation ...

Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Obesity is a complex, treatable medical condition, not just a matter of willpower, requiring a shift in perception and ...

Biologic age is determined by measuring how well the body’s cells and organs are functioning. This is different than ...

PE: What makes TrumpRx different from other government-run health programs? O’Dell: TrumpRx is different in that its ...